News Archives
Gedeon Richter and Myovant Sciences Receive Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Uterine Fibroids
in News, Press Releases onRead more21 May 2021 Budapest, Hungary – 21 May 2021 – Gedeon Richter Plc. (“Richter”) announces that the Committee for…
0Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
in News, Press Releases onRead more31 March 2020 Budapest, Hungary and Basel, Switzerland – Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative…
Richter announces the acquisition of Finox Holding
in News, Press Releases onRead more30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. Finox Holding, a…
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
in News, Press Releases onRead moreDUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, — Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive…
Full Results of PEARL IV Study presented at the European Society of Gynaecological Endoscopy (ESGE) congress confirms the efficacy of ulipristal acetate 5 mg for the long term management of uterine fibroids
in Events, Press Releases onRead moreBudapest, 12 October 2015 – Gedeon Richter Plc. (“Richter”) announces results of the PEARL IV study at ESGE. PEARL IV…
European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 28 May 2015 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted approval…
European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
in News, Press Releases onRead moreBudapest, Hungary, 27 January 2013: Gedeon Richter Plc. (“Richter”) announces that Esmya® 5 mg tablets (ulipristal acetate) is now licensed…
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 27 February 2012 – Gedeon Richter Plc. (“Richter”) announces today that the European Commission (EC) has granted…
PEARL I and II studies published in New England Journal of Medicine confirm the efficacy of Esmya® (ulipristal acetate) for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreGeneva, Switzerland – 2 February 2012 – PregLem, the wholly owned subsidiary of Gedeon Richter, announces full results of PEARL…
Richter announces that PregLem, its wholly owned subsidiary, receives positive EMA/CHMP opinion for Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onRead moreBudapest, Hungary – 16 December 2011 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human…
Careers
A career at Preglem® is more than just a job. It gives you the opportunity to solve challenging global problems in a way that can change the world.
Contact us
In line with our corporate culture, we treat all information received with full confidentiality.